Yahoo Finance

Overview: Verve Therapeutics, Inc. is a clinical-stage company focused on developing gene editing medicines for treating cardiovascular disease in the United States, with a market cap of $289.47 million.

Operations: The company generates revenue from its Pharmaceuticals segment, amounting to $32.33 million.

Market Cap: $289.47M

Verve Therapeutics, with a market cap of US$289.47 million, is currently unprofitable but debt-free and maintains a solid cash runway for over three years based on its current free cash flow. The company recently announced positive initial data from its Heart-2 Phase 1b clinical trial for VERVE-102, targeting LDL-C reduction in patients with HeFH or premature CAD. Despite high share price volatility and declining earnings forecasts, Verve's short-term assets significantly exceed liabilities, providing financial stability to support ongoing trials. The FDA clearance of their IND application marks a key milestone as they prepare for Phase 2 trials later this year.

• Jump into the full analysis health report here for a deeper understanding of Verve Therapeutics.

• Understand Verve Therapeutics' earnings outlook by examining our growth report.

United States Antimony

Simply Wall St Financial Health Rating: ★★★★★★

Overview: United States Antimony Corporation is engaged in the production and sale of antimony, silver, gold, precious metals, and zeolite products in the United States and Canada, with a market cap of $319.82 million.

Operations: The company generates revenue through its two main segments: Antimony, contributing $12 million, and Zeolite, adding approximately $2.94 million.

Market Cap: $319.82M

United States Antimony Corporation, with a market cap of US$319.82 million, is unprofitable but has a solid cash runway exceeding three years and more cash than total debt. Despite high share price volatility and an inexperienced management team, the company’s short-term assets of US$20.7 million comfortably cover both short- and long-term liabilities. Earnings are forecast to grow significantly at 63.27% annually, although past losses have increased by 9.8% per year over five years. The upcoming earnings release on March 20 may provide further insights into its financial trajectory amidst industry challenges.

• Click here and access our complete financial health analysis report to understand the dynamics of United States Antimony.

• Gain insights into United States Antimony's future direction by reviewing our growth report.

Make It Happen

• Unlock our comprehensive list of 785 US Penny Stocks by clicking here.

• Seeking Other Investments? Trump's oil boom is here — pipelines are primed to profit. Discover the 20 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGS:CLOV NasdaqGS:VERV and NYSEAM:UAMY.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com